Insuman Basal Solostar

Insulin human, the active ingredient in Insuman Basal Solostar, is an insulin presented as a solution for subcutaneous injection use. It treats Type 1 and Type 2 diabetes mellitus by providing basal insulin coverage.

GNH USA supplies Insuman Basal Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Basal Solostar is a basal insulin used to manage chronic hyperglycaemia in diabetes.

- Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: adds basal insulin to oral agents for improved glycaemic control. - Insulin deficiency states (e.g., post‑pancreatectomy): supplies necessary basal insulin to replace endogenous production.

Insuman Basal Solostar may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with insulin therapy. - Lipodystrophy: localized changes in fat tissue at repeated injection sites.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycaemia with seizures or loss of consciousness. - Insulin antibody formation: may alter insulin action and cause unpredictable glucose levels. - Acute lipohypertrophy leading to erratic insulin absorption.

When using Insuman Basal Solostar, several precautions should be observed to ensure safe and effective therapy.

- Dose individualisation: adjust dose based on blood glucose monitoring and clinical response. - Monitor hypoglycaemia: educate patients to recognise and treat low blood glucose promptly. - Illness or stress: anticipate higher insulin requirements during infection or physiological stress. - Renal or hepatic impairment: use caution and consider dose reduction in organ dysfunction. - Concomitant medications: be aware of agents that may mask hypoglycaemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal Solostar can interact with other medicines, affecting glucose control or insulin action.

Major Interactions (Avoid): - Concurrent use of other insulin products: risk of severe hypoglycaemia from additive insulin effect. - Beta‑blockers: may mask typical hypoglycaemia symptoms such as tachycardia. - Glucocorticoids: can markedly increase blood glucose, necessitating insulin dose adjustments.

Moderate Interactions (Monitor Closely): - Sulfonylureas or other oral hypoglycaemics: additive glucose‑lowering effect may require dose reduction. - Thiazide diuretics: may raise blood glucose levels, potentially requiring higher insulin dose. - ACE inhibitors: may enhance insulin sensitivity, warranting closer glucose monitoring.